Are you at least 21 years old?
You must be at least 21 to see this content, you will be redirected to google
Are you at least 21 years old?
You must be at least 21 to see this content, you will be redirected to google
A
• amyotrophic-lateral-sclerosis-als-lou-gehrigs (2)
• attention-deficit-hyperactivity-disorder-adhd (5)
B
C
D
• d9-tetrahydrocannabinol-thc (4)
• d9-tetrahydrocannabinolic-acid-thca (1)
E
• endocannabinoid-system-ecs (45)
F
G
• gastrointestinal-disease (6)
H
I
K
L
M
N
• national-institute-on-drug-abuse-nida (1)
• neuro-protective-and-neuro-generative (7)
P
S
T
• traumatic-brain-injury-tbi (1)
• View All (505)Role of myeloid-derived suppressor cells in amelioration of experimental autoimmune hepatitis following activation of TRPV1 receptors by cannabidiol (2011)
Role of the Cannabinoid System in Pain Control and Therapeutic Implications for the Management of Acute and Chronic Pain Episodes (2006)
Cannabis extracts and synthetic cannabinoids are still considered illegal substances. Studies suggest that they can be useful for treating various diseases, including those related to acute or chronic pain. The objective of this review was to examine the promising indications of cannabinoid receptor agonists to relieve episodes of acute and chronic pain. View study
Role of the Endocannabinoid System in the Neuroendocrine Responses to Inflammation (2014)
For several years the endocannabinoid system has been recognized as an important neuromodulator system whose main functions are to exercise and maintain the homeostasis of the body. The present review focused on the actions of endocannabinoids on the neuroendocrine response to inflammation and infection. View study
Safety and efficacy of a novel cannabinoid chemotherapeutic, KM-233, for the treatment of high-grade glioma ()
The median historical survival of patients with glioblastoma multiforme (GBM) with the best radiological, surgical and antitumor pharmacological treatment available is less than one year, depending on age and other prognostic factors. This research aimed to test in vitro and in vitro the safety and efficacy of a new chemotherapeutic agent KM-233 for the treatment of glioma. It could be concluded that these studies provided both in vitro and in vitro evidence that KM-233 shows promising efficacy against human glioma cell lines in both in vitro and in vitro studies View study
Safety and Side Effects of Cannabidiol, a Cannabis sativa Constituent (2011)
Safety and Toxicology of Cannabinoids (2015)
This review will provide a brief description of cannabinoids and the endocannabinoid system; a summary of the acute and long-term effects of cannabis; and a discussion about the therapeutic potential of cannabis. View study
Sativex in the Management of Multiple Sclerosis-Related Spasticity: Role of the Corticospinal Modulation ()
Short-term effects of cannabinoids in patients with HIV-1 infection (2003)
The use of cannabinoids could potentially alter RNA levels. The present investigation is based on determining the short-term effects of smoked marijuana on viral load in HIV-infected patients. View study
siRNA knockdown of GPR18 receptors in BV-2 microglia attenuates N-arachidonoyl glycineinduced cell migration (2012)
It is known that neurons use the endogenous cannabinoid system to communicate with other cells of the central nervous system (CNS). Endocannabioid signaling recruits microglia to neurons by activating the cannabinoid CB2 and abnormal receptors of cannabidiol (Abn-CBD). The present study focused on the study of siRNA knockdown of GPR18 receptors in BV-2 microglia attenuates N-arachidonoyl glycineinduced cell migration View study
Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial ()
Species differences in cannabinoid receptor 2 (CNR2 gene): identification of novel human and rodent CB2 isoforms, differential tissue expression and regulation by cannabinoid receptor ligands (2009)
The results of this study suggest that the cannabinoid CB2-R could be involved in the mechanisms of endocannabinoid signaling associated with the regulation of emotionality. More studies are needed to determine if the CB2-R ligands increase the risk of depression or suicide (which led to the recall of Rimonabant as an appetite suppressant in the control of obesity). View study
Stimulation of brain glucose uptake by cannabinoid CB2 receptors and its therapeutic potential in Alzheimer�s disease (2016)
This study was conducted on CB2R cannabinoid receptors (CB2R) in order to analyze their potential as therapeutic targets. It was found that CB2R has a general role of glucoregulation in the brain, which increases the therapeutic interest in CB2R agonists as nootropic agents. View study